Permixon, 160 mg capsules 30 pcs

Permixon has a complex effect on the pathogenesis and symptoms of benign prostatic hyperplasia due to the complementary effects of the constituent ingredients of this herbal extract.

Permixon has anti-androgenic, anti-inflammatory, anti-inflammatory and anti-proliferative effects, which are selectively expressed at the level of the prostate gland. At the same time the preparation does not influence the level of sex hormones in blood, does not cause deterioration of sexual functions, libido and potency and does not change the level of serum PSA (prostate-specific antigen).

The local anti-androgenic effect of Permixon is associated with the inhibition of 5-alpha-reductase enzyme of types I and II, responsible for the conversion of testosterone in the prostate into its active form – dihydrotestosterone, and reduction of its binding to specific receptors. Reducing the formation of dihydrotestosterone leads to a decrease in further growth of the prostate.

Local anti-inflammatory effect is due to the impact of lipidosterol extract serenoa creeping on the main mediators of cellular inflammation – inhibits the activity of phospholipase A2, cyclooxygenase and lipooxygenase.

Permixon during the first weeks of treatment reduces capillary permeability and vascular stasis, relieves edema and inflammation of the prostate, eliminates compression of the bladder neck and urinary tract and, like alpha-blockers, improves urodynamic indices.

Local antiproliferative action of the preparation is manifested by decrease of activity of growth factors (first of all epidermal and fibroblastic) and acceleration of apoptosis processes of prostate cells which is reflected in inhibition of growth and subsequent decrease of prostate gland volume.

These properties of the preparation help to reduce pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nycturia, painful sensations and tension while urination, incomplete emptying of the bladder) and increase the volume and force of urination.

On the other hand, Permixon promotes inhibition of further growth and volume of the prostate gland.

Indications

Benign prostatic hyperplasia (adenoma) stage I and II.

Active ingredient

Composition

How to take, the dosage

Overly, with meals, 160 mg (1 capsule) 2 times a day or once in the morning.

Interaction

Compatible with the drugs most commonly used in the treatment of obstructive and inflammatory prostate diseases (antibiotics, uroantiseptics, anti-inflammatory drugs).

Contraindications

Side effects

In some cases, nausea, heartburn, gastralgia may occur, which usually disappear when taking the drug with food. In rare cases – allergic reactions.

.

Similarities